文献速递心脑血管急症

急性冠脉综合征患者PCI术后基于普拉格雷的双联抗血小板治疗降阶:HOST-REDUCE-POLYTECH-ACS开放标签多中心非劣效随机试验

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
PubMed 文献 · Lancet · 2020-08-31
一句话结论东亚急性冠脉综合征PCI术后患者,普拉格雷10mg治疗1个月后降阶至5mg,1年内净不良临床事件非劣于持续10mg,主要由出血减少驱动且未增加缺血风险。

HOST-REDUCE-POLYTECH-ACS是在韩国35家医院开展的随机、开放标签、多中心、非劣效试验,纳入接受PCI的急性冠脉综合征患者,随机分为降阶组(普拉格雷10mg+阿司匹林100mg每日1个月后改为普拉格雷5mg)或常规组(持续普拉格雷10mg),主要终点为1年净不良临床事件。降阶组主要终点发生82例(Kaplan-Meier估计7.2%),常规组116例(10.1%),绝对风险差-2.9%,非劣效P<0.0001,HR 0.70(95%CI 0.52-0.92),等效性P=0.012。降阶组缺血风险未增加(HR 0.76,95%CI 0.40-1.45,P=0.40),出血事件风险显著降低(HR 0.48,95%CI 0.32-0.73,P=0.0007)。作者认为,在东亚急性冠脉综合征PCI术后患者中,术后1个月开始基于普拉格雷的剂量降阶策略可降低1年内净临床结局风险,主要由出血减少驱动且未增加缺血。

要点

  • 东亚急性冠脉综合征PCI术后患者,普拉格雷10mg+阿司匹林100mg每日治疗1个月后降阶至普拉格雷5mg,1年净不良临床事件非劣于持续10mg(7.2% vs 10.1%,绝对风险差-2.9%,非劣效P<0.0001)。
  • 降阶组1年净不良临床事件HR 0.70(95%CI 0.52-0.92),等效性P=0.012。
  • 降阶组出血事件(BARC≥2级)风险显著低于常规组(HR 0.48,95%CI 0.32-0.73,P=0.0007)。
  • 降阶组缺血复合终点(心血管死亡、心肌梗死、支架血栓、缺血性卒中)与常规组无显著差异(HR 0.76,95%CI 0.40-1.45,P=0.40)。
  • 作者认为,术后1个月开始基于普拉格雷的剂量降阶策略可降低1年净临床结局风险,主要由出血减少驱动且未增加缺血。

适用人群与场景

  • 接受PCI的急性冠脉综合征患者,且符合普拉格雷核心适应证。
  • 排除不符合普拉格雷核心适应证的患者(1075例被筛查排除)及随机化错误者(16例被排除)。
  • 研究在韩国35家医院开展,纳入东亚人群。

诊断标准与关键阈值

  • 主要终点:1年净不良临床事件,包括全因死亡、非致死性心肌梗死、支架血栓、重复血运重建、卒中及BARC≥2级出血事件。
  • 非劣效界值:主要终点绝对非劣效界值为2.5%。

处置流程与药物剂量

  • 所有患者先接受普拉格雷10mg+阿司匹林100mg每日治疗1个月。
  • 1个月后,降阶组改为普拉格雷5mg每日(阿司匹林100mg每日继续),常规组继续普拉格雷10mg每日。
  • 治疗持续至1年。

研究设计与关键结果

  • 研究类型:随机、开放标签、多中心、非劣效试验,在韩国35家医院开展,共随机2338例患者(降阶组n=1170,常规组n=1168),主要分析为意向性治疗人群。
  • 主要终点:降阶组82例(Kaplan-Meier估计7.2%)vs 常规组116例(10.1%),绝对风险差-2.9%,非劣效P<0.0001,HR 0.70(95%CI 0.52-0.92),等效性P=0.012。
  • 关键次要终点-缺血复合终点(心血管死亡、心肌梗死、支架血栓、缺血性卒中):降阶组vs常规组HR 0.76(95%CI 0.40-1.45),P=0.40,无显著差异。
  • 关键次要终点-出血事件(BARC≥2级):降阶组vs常规组HR 0.48(95%CI 0.32-0.73),P=0.0007,降阶组显著降低。

证据类型、等级与局限

  • 证据类型:随机、开放标签、多中心、非劣效试验(RCT)。
  • 评估者设盲,随机化通过基于网络的系统进行。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在东亚急性冠脉综合征PCI术后患者中,术后1个月将普拉格雷从10mg降阶至5mg每日,可降低1年净不良临床事件风险,主要由出血减少驱动且未增加缺血风险(作者结论)。
  • 该策略适用于符合普拉格雷核心适应证且已接受普拉格雷10mg+阿司匹林100mg每日治疗1个月的急性冠脉综合征PCI术后患者。
  • 研究为开放标签设计,需注意评估者设盲而患者和医生未设盲的潜在偏倚。

指南或共识出处

  • HOST-REDUCE-POLYTECH-ACS试验,注册号NCT02193971,发表于Lancet。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A potent P2Y12 inhibitor-based dual antiplatelet therapy is recommended for up to 1 year in patients with acute coronary syndrome receiving percutaneous coronary intervention (PCI). The greatest benefit of the potent agent is during the early phase, whereas the risk of excess bleeding continues in the chronic maintenance phase. Therefore, de-escalation of antiplatelet therapy might achieve an optimal balance between ischaemia and bleeding. We aimed to investigate the safety and efficacy of a prasugrel-based dose de-escalation therapy.

METHODS: HOST-REDUCE-POLYTECH-ACS is a randomised, open-label, multicentre, non-inferiority trial done at 35 hospitals in South Korea. We enrolled patients with acute coronary syndrome receiving PCI. Patients meeting the core indication for prasugrel were randomly assigned (1:1) to the de-escalation group or conventional group using a web-based randomisation system. The assessors were masked to the treatment allocation. After 1 month of treatment with 10 mg prasugrel plus 100 mg aspirin daily, the de-escalation group received 5 mg prasugrel, while the conventional group continued to receive 10 mg. The primary endpoint was net adverse clinical events (all-cause death, non-fatal myocardial infarction, stent thrombosis, repeat revascularisation, stroke, and bleeding events of grade 2 or higher according to Bleeding Academic Research Consortium [BARC] criteria) at 1 year. The absolute non-inferiority margin for the primary endpoint was 2·5%. The key secondary endpoints were efficacy outcomes (cardiovascular death, myocardial infarction, stent thrombosis, and ischaemic stroke) and safety outcomes (bleeding events of BARC grade ≥2). The primary analysis was in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02193971.

RESULTS: From Sept 30, 2014, to Dec 18, 2018, 3429 patients were screened, of whom 1075 patients did not meet the core indication for prasugrel and 16 were excluded due to randomisation error. 2338 patients were randomly assigned to the de-escalation group (n=1170) or the conventional group (n=1168). The primary endpoint occurred in 82 patients (Kaplan-Meier estimate 7·2%) in the de-escalation group and 116 patients (10·1%) in the conventional group (absolute risk difference -2·9%, pnon-inferiority<0·0001; hazard ratio 0·70 [95% CI 0·52-0·92], pequivalence=0·012). There was no increase in ischaemic risk in the de-escalation group compared with the conventional group (0·76 [0·40-1·45]; p=0·40), and the risk of bleeding events was significantly decreased (0·48 [0·32-0·73]; p=0·0007).

INTERPRETATION: In east Asian patients with acute coronary syndrome patients receiving PCI, a prasugrel-based dose de-escalation strategy from 1 month after PCI reduced the risk of net clinical outcomes up to 1 year, mainly driven by a reduction in bleeding without an increase in ischaemia.

FUNDING: Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, Qualitech Korea, and Dio.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020. PMID: 32882163. doi:10.1016/S0140-6736(20)31791-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。